BPGbio to Present Phase 2 Data on Novel Mitochondrial-Targeted Therapy BPM31510 for Glioblastoma at ASCO 2026
Key Insights
BPGbio (search) will present trial-in-progress data from its ongoing Phase 2 study of BPM31510, a first-in-class mitochondrial-targeted therapy for newly diagnosed glioblastoma multiforme (search) at ASCO 2026.
BPM31510, a lipid nanodispersion of oxidized CoQ10, demonstrated PET-confirmed reversal of the Warburg effect in Phase 1 trials, shifting tumor metabolism from glycolysis to oxidative phosphorylation.
The investigational therapy targets dysregulated mitochondrial metabolism (search) in cancer (search) cells and aims to sensitize glioblastoma (search) patients to radiotherapy through BCL-2 (search) protein family targeting.
BPGbio (search) announced that clinical progress data from its ongoing Phase 2 study of BPM31510 in newly diagnosed glioblastoma multiforme (search) (GBM) will be presented at the upcoming ASCO Annual Meeting. The trial-in-progress poster will be presented by Seema Nagpal, M.D., Principal Investigator of the study and Professor of Neurology and Neurological Sciences at Stanford Medicine.
Novel Mitochondrial-Targeted Approach
BPM31510 represents a first-in-class therapeutic targeting tumor metabolism to reprogram the mitochondrial microenvironment in Warburg-avid tumors. The investigational therapy is a lipid nanodispersion formulation of oxidized Coenzyme Q10 (CoQ10), administered with vitamin K1 in combination with standard-of-care radiation therapy and temozolomide in patients with newly diagnosed GBM who have not received prior therapy.
The drug is designed to target dysregulated mitochondrial metabolism (search) in cancer (search) cells by modulating mitochondrial function and restoring oxidative balance. BPM31510 aims to induce tumor-selective redox stress while helping preserve healthy tissue metabolism, seeking to re-engage mitochondrial pathways that may contribute to tumor cell vulnerability in highly aggressive cancers such as glioblastoma (search).
Promising Phase 1 Results
According to Vivek Subbiah, M.D., Jeffrey and Christina Bird Endowed Chair and Professor of Medicine at Stanford Cancer Institute, "The BPM31510 phase I trial delivered pharmacodynamic proof, PET-confirmed reversal of the Warburg effect, shifting tumor metabolism from glycolysis to oxidative phosphorylation at supraphysiologic CoQ10 concentrations."
The metabolic reprogramming drives a ROS-mediated, BCL-2 (search)–dependent apoptotic cascade that may unlock glioblastoma (search)'s mitochondrial vulnerability. The direct targeting of the BCL-2 protein family serves to sensitize patients to radiotherapy, potentially enhancing treatment efficacy.
Addressing Critical Unmet Need
Glioblastoma (search) is the most common and aggressive malignant primary brain tumor (search) in adults and is associated with poor survival despite multimodal treatment approaches. Dr. Subbiah noted that for patients with GBM, "a devastating disease where median survival remains under two years despite decades of research, the ongoing front-line study is a test of whether this science can translate into a meaningful survival benefit."
Increasing evidence suggests that altered mitochondrial metabolism (search) plays a critical role in glioblastoma (search) progression, treatment resistance, and tumor adaptation, making mitochondrial targeting a potentially important therapeutic approach.
Clinical Development Strategy
The ongoing Phase 2 study will highlight both safety profile and efficacy data in methylated and unmethylated GBM tumors. The study builds upon prior clinical and translational research evaluating BPM31510 across oncology indications and reflects BPGbio (search)'s broader focus on targeting mitochondrial dysfunction in diseases with significant unmet medical need.
"Glioblastoma (search) remains one of the most devastating cancers, with limited therapeutic advances for patients in recent decades," said Niven R. Narain, Ph.D, President and Chief Executive Officer of BPGbio (search). "We believe mitochondrial targeting represent an important and underexplored therapeutic frontier in GBM in oncology."
Broader Development Program
BPM31510 is being evaluated across oncology and rare disease indications, including glioblastoma multiforme (search), pancreatic cancer (search), and Primary CoQ10 Deficiency (search). The investigational therapy has received Orphan Drug Designation and Pediatric Rare Disease Designation from the U.S. Food and Drug Administration for multiple indications.
The ASCO presentation will take place on Monday, June 1, 2026, from 1:30 PM to 4:30 PM CDT during the Poster Session for Central Nervous System Tumors (Abstract Number: TPS2101, Poster Board: 461b).